Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 4.93
LXRX's Cash to Debt is ranked lower than
64% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: 61.14 vs. LXRX: 4.93 )
Ranked among companies with meaningful Cash to Debt only.
LXRX' s Cash to Debt Range Over the Past 10 Years
Min: 1.85  Med: 4.93 Max: No Debt
Current: 4.93
Equity to Asset 0.44
LXRX's Equity to Asset is ranked lower than
76% of the 705 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. LXRX: 0.44 )
Ranked among companies with meaningful Equity to Asset only.
LXRX' s Equity to Asset Range Over the Past 10 Years
Min: 0.36  Med: 0.64 Max: 0.94
Current: 0.44
0.36
0.94
Interest Coverage 0.22
LXRX's Interest Coverage is ranked lower than
99% of the 393 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. LXRX: 0.22 )
Ranked among companies with meaningful Interest Coverage only.
LXRX' s Interest Coverage Range Over the Past 10 Years
Min: 0.22  Med: 0.22 Max: 0.22
Current: 0.22
F-Score: 5
Z-Score: 0.98
M-Score: 1.63
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 1.13
LXRX's Operating margin (%) is ranked higher than
70% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -66.05 vs. LXRX: 1.13 )
Ranked among companies with meaningful Operating margin (%) only.
LXRX' s Operating margin (%) Range Over the Past 10 Years
Min: -9955.46  Med: -639.94 Max: 1.13
Current: 1.13
-9955.46
1.13
Net-margin (%) -3.60
LXRX's Net-margin (%) is ranked higher than
67% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -68.08 vs. LXRX: -3.60 )
Ranked among companies with meaningful Net-margin (%) only.
LXRX' s Net-margin (%) Range Over the Past 10 Years
Min: -10120.39  Med: -606.25 Max: -3.6
Current: -3.6
-10120.39
-3.6
ROE (%) -1.86
LXRX's ROE (%) is ranked higher than
73% of the 859 Companies
in the Global Biotechnology industry.

( Industry Median: -31.46 vs. LXRX: -1.86 )
Ranked among companies with meaningful ROE (%) only.
LXRX' s ROE (%) Range Over the Past 10 Years
Min: -63.41  Med: -43.42 Max: -1.64
Current: -1.86
-63.41
-1.64
ROA (%) -0.98
LXRX's ROA (%) is ranked higher than
75% of the 939 Companies
in the Global Biotechnology industry.

( Industry Median: -26.29 vs. LXRX: -0.98 )
Ranked among companies with meaningful ROA (%) only.
LXRX' s ROA (%) Range Over the Past 10 Years
Min: -32.59  Med: -27.19 Max: -0.83
Current: -0.98
-32.59
-0.83
ROC (Joel Greenblatt) (%) 27.31
LXRX's ROC (Joel Greenblatt) (%) is ranked higher than
86% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: -363.62 vs. LXRX: 27.31 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
LXRX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -414.95  Med: -161.37 Max: 70.58
Current: 27.31
-414.95
70.58
Revenue Growth (3Y)(%) 328.10
LXRX's Revenue Growth (3Y)(%) is ranked higher than
99% of the 474 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. LXRX: 328.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
LXRX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -71.6  Med: -3.40 Max: 328.1
Current: 328.1
-71.6
328.1
EPS Growth (3Y)(%) -69.40
LXRX's EPS Growth (3Y)(%) is ranked lower than
97% of the 487 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. LXRX: -69.40 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
LXRX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -69.4  Med: -13.25 Max: 30.9
Current: -69.4
-69.4
30.9
» LXRX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

LXRX Guru Trades in Q1 2015

Joel Greenblatt 73,566 sh (New)
Jim Simons 1,636,131 sh (+135.11%)
Chuck Royce 2,813,833 sh (unchged)
Mario Gabelli 105,200 sh (unchged)
Paul Tudor Jones 29,223 sh (-45.17%)
» More
Q2 2015

LXRX Guru Trades in Q2 2015

Joel Greenblatt Sold Out
Paul Tudor Jones Sold Out
Mario Gabelli 14,285 sh (-86.42%)
Chuck Royce 377,074 sh (-86.60%)
Jim Simons 170,153 sh (-89.60%)
» More
Q3 2015

LXRX Guru Trades in Q3 2015

Paul Tudor Jones 15,299 sh (New)
Mario Gabelli 14,285 sh (unchged)
Chuck Royce 334,374 sh (-11.32%)
Jim Simons 11,086 sh (-93.48%)
» More
Q4 2015

LXRX Guru Trades in Q4 2015

Mario Gabelli 16,100 sh (+12.71%)
Paul Tudor Jones Sold Out
Jim Simons Sold Out
Chuck Royce 259,589 sh (-22.37%)
» More
» Details

Insider Trades

Latest Guru Trades with LXRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Price/Owner Earnings (ttm) 8.20
LXRX's Price/Owner Earnings (ttm) is ranked higher than
86% of the 143 Companies
in the Global Biotechnology industry.

( Industry Median: 33.75 vs. LXRX: 8.20 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
LXRX' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 5.2  Med: 19.61 Max: 27.88
Current: 8.2
5.2
27.88
P/B 5.04
LXRX's P/B is ranked lower than
65% of the 843 Companies
in the Global Biotechnology industry.

( Industry Median: 3.49 vs. LXRX: 5.04 )
Ranked among companies with meaningful P/B only.
LXRX' s P/B Range Over the Past 10 Years
Min: 0.66  Med: 3.10 Max: 10.19
Current: 5.04
0.66
10.19
P/S 11.01
LXRX's P/S is ranked higher than
50% of the 674 Companies
in the Global Biotechnology industry.

( Industry Median: 11.42 vs. LXRX: 11.01 )
Ranked among companies with meaningful P/S only.
LXRX' s P/S Range Over the Past 10 Years
Min: 2.62  Med: 24.28 Max: 1440
Current: 11.01
2.62
1440
PFCF 7.77
LXRX's PFCF is ranked higher than
89% of the 114 Companies
in the Global Biotechnology industry.

( Industry Median: 30.93 vs. LXRX: 7.77 )
Ranked among companies with meaningful PFCF only.
LXRX' s PFCF Range Over the Past 10 Years
Min: 4.92  Med: 19.20 Max: 22.78
Current: 7.77
4.92
22.78
POCF 7.72
LXRX's POCF is ranked higher than
84% of the 175 Companies
in the Global Biotechnology industry.

( Industry Median: 25.07 vs. LXRX: 7.72 )
Ranked among companies with meaningful POCF only.
LXRX' s POCF Range Over the Past 10 Years
Min: 4.9  Med: 10.90 Max: 45.01
Current: 7.72
4.9
45.01
EV-to-EBIT 498.81
LXRX's EV-to-EBIT is ranked lower than
98% of the 256 Companies
in the Global Biotechnology industry.

( Industry Median: 24.70 vs. LXRX: 498.81 )
Ranked among companies with meaningful EV-to-EBIT only.
LXRX' s EV-to-EBIT Range Over the Past 10 Years
Min: -14.9  Med: -2.60 Max: 525.24
Current: 498.81
-14.9
525.24
EV-to-EBITDA 367.74
LXRX's EV-to-EBITDA is ranked lower than
97% of the 275 Companies
in the Global Biotechnology industry.

( Industry Median: 20.64 vs. LXRX: 367.74 )
Ranked among companies with meaningful EV-to-EBITDA only.
LXRX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -15.1  Med: -2.80 Max: 387.22
Current: 367.74
-15.1
387.22
Current Ratio 4.33
LXRX's Current Ratio is ranked lower than
54% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.77 vs. LXRX: 4.33 )
Ranked among companies with meaningful Current Ratio only.
LXRX' s Current Ratio Range Over the Past 10 Years
Min: 1.19  Med: 6.25 Max: 19.93
Current: 4.33
1.19
19.93
Quick Ratio 4.33
LXRX's Quick Ratio is ranked lower than
52% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. LXRX: 4.33 )
Ranked among companies with meaningful Quick Ratio only.
LXRX' s Quick Ratio Range Over the Past 10 Years
Min: 1.19  Med: 6.25 Max: 19.93
Current: 4.33
1.19
19.93
Days Sales Outstanding 2.56
LXRX's Days Sales Outstanding is ranked higher than
96% of the 603 Companies
in the Global Biotechnology industry.

( Industry Median: 66.24 vs. LXRX: 2.56 )
Ranked among companies with meaningful Days Sales Outstanding only.
LXRX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 2.56  Med: 22.17 Max: 461.86
Current: 2.56
2.56
461.86

Valuation & Return

vs
industry
vs
history
Price/Net Cash 9.39
LXRX's Price/Net Cash is ranked lower than
65% of the 496 Companies
in the Global Biotechnology industry.

( Industry Median: 5.74 vs. LXRX: 9.39 )
Ranked among companies with meaningful Price/Net Cash only.
LXRX' s Price/Net Cash Range Over the Past 10 Years
Min: 2.84  Med: 4.52 Max: 37.03
Current: 9.39
2.84
37.03
Price/Net Current Asset Value 8.74
LXRX's Price/Net Current Asset Value is ranked lower than
64% of the 616 Companies
in the Global Biotechnology industry.

( Industry Median: 5.40 vs. LXRX: 8.74 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
LXRX' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.45  Med: 4.64 Max: 59.01
Current: 8.74
2.45
59.01
Price/Tangible Book 7.63
LXRX's Price/Tangible Book is ranked lower than
70% of the 776 Companies
in the Global Biotechnology industry.

( Industry Median: 4.27 vs. LXRX: 7.63 )
Ranked among companies with meaningful Price/Tangible Book only.
LXRX' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.2  Med: 3.40 Max: 12.82
Current: 7.63
1.2
12.82
Price/Median PS Value 0.45
LXRX's Price/Median PS Value is ranked higher than
84% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. LXRX: 0.45 )
Ranked among companies with meaningful Price/Median PS Value only.
LXRX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.13  Med: 0.61 Max: 41.81
Current: 0.45
0.13
41.81
Earnings Yield (Greenblatt) (%) 0.21
LXRX's Earnings Yield (Greenblatt) (%) is ranked higher than
73% of the 900 Companies
in the Global Biotechnology industry.

( Industry Median: -7.60 vs. LXRX: 0.21 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
LXRX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.2  Med: 19.60 Max: 1944.4
Current: 0.21
0.2
1944.4

More Statistics

Revenue(Mil) $130
EPS $ -0.05
Beta-0.46
Short Percentage of Float55.83%
52-Week Range $6.66 - 15.79
Shares Outstanding(Mil)103.77

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 69 49 128
EPS($) -1.28 -1.73 -0.74
EPS without NRI($) -1.28 -1.73 -0.74

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:AGIO, SZSE:300009, XKRX:086900, SZSE:300294, SHSE:600200, NAS:BLUE » details
Traded in other countries:LX31.Germany,
Lexicon Pharmaceuticals Inc was incorporated in Delaware on July 7, 1995. The Company operates as a biopharmaceutical company engaged in discovery and development of breakthrough treatments for human disease. It has used its proprietary gene knockout technology and an integrated platform of advanced medical technologies to systematically study the physiological and behavioral functions of almost 5,000 genes in mice and assessed the utility of the proteins encoded by the corresponding human genes as potential drug targets. It has identified and validated in living animals, or in vivo, more than 100 targets with promising profiles for drug discovery. The Company has also advanced small molecule compounds from a number of additional drug programs into various stages of preclinical development and research and believe that its systematic, target biology-driven approach to drug discovery will enable it to continue to expand its clinical pipeline. It faces significant competition in each of the aspects of its business from other pharmaceutical and biotechnology companies. The development, manufacture and sale of any drug or biologic products developed by the Company or its collaborators will be subject to extensive regulation by United States and foreign governmental authorities, including federal, state and local authorities.
» More Articles for NAS:LXRX

Headlines

Articles On GuruFocus.com
Lexicon Genetics Inc. Reports Operating Results (10-Q) Nov 08 2010 
Lexicon Genetics Inc. Reports Operating Results (10-Q) Aug 09 2010 
Lexicon Genetics Inc. Reports Operating Results (10-Q) May 10 2010 
Lexicon Genetics Inc. Reports Operating Results (10-Q) Oct 30 2009 
Lexicon Genetics Inc. Reports Operating Results (10-Q) Aug 06 2009 
Lexicon Genetics Inc. Reports Operating Results (10-Q) Apr 30 2009 

More From Other Websites
Lexicon to Report First Quarter 2016 Financial Results on May 3, 2016 Apr 29 2016
Lexicon To Report First Quarter 2016 Financial Results On May 3, 2016 Apr 29 2016
ETF’s with exposure to Lexicon Pharmaceuticals, Inc. : April 29, 2016 Apr 29 2016
LEXICON PHARMACEUTICALS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security... Apr 28 2016
ETF’s with exposure to Lexicon Pharmaceuticals, Inc. : April 8, 2016 Apr 07 2016
Lexicon to Present at the 15th Annual Needham Healthcare Conference Apr 07 2016
Lexicon To Present At The 15th Annual Needham Healthcare Conference Apr 07 2016
Lexicon Pharmaceuticals, Inc. :LXRX-US: Earnings Analysis: Q4, 2015 By the Numbers Apr 06 2016
Lexicon Pharmaceuticals, Inc. :LXRX-US: Earnings Analysis: 2015 By the Numbers Apr 06 2016
LEXICON PHARMACEUTICALS, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement Apr 01 2016
Lexicon Submits New Drug Application to FDA for Telotristat Etiprate for the Treatment of Carcinoid... Mar 30 2016
Lexicon Submits New Drug Application To FDA For Telotristat Etiprate For The Treatment Of Carcinoid... Mar 30 2016
LEXICON PHARMACEUTICALS, INC. Financials Mar 17 2016
LEXICON PHARMACEUTICALS, INC. Files SEC form 10-K, Annual Report Mar 11 2016
Lexicon Announces Telotristat Etiprate Data To Be Presented At European Neuroendocrine Tumor Society... Mar 08 2016
Lexicon To Present At The 36th Annual Cowen Healthcare Conference Mar 03 2016
Lexicon Pharmaceuticals, Inc. – Value Analysis (NASDAQ:LXRX) : March 3, 2016 Mar 03 2016
Lexicon Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : LXRX-US :... Mar 02 2016
Edited Transcript of LXRX earnings conference call or presentation 1-Mar-16 3:00pm GMT Mar 01 2016
Can These Biotech Stocks Remedy Your Portfolio? – RARE, LXRX, ESPR, and INSM Mar 01 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK